GTBP Ebitda from 2010 to 2024
| GTBP Stock | USD 3.08 0.23 8.07% |
EBITDA | First Reported 1985-09-30 | Previous Quarter -3.2 M | Current Value -3.1 M | Quarterly Volatility 10.8 M |
Check GT Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GT Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.3 M, Interest Expense of 202.3 K or Selling General Administrative of 8.8 M, as well as many indicators such as Price To Sales Ratio of 2.3 K, Dividend Yield of 0.0 or PTB Ratio of 1.31. GTBP financial statements analysis is a perfect complement when working with GT Biopharma Valuation or Volatility modules.
GTBP | Ebitda |
Latest GT Biopharma's Ebitda Growth Pattern
Below is the plot of the Ebitda of GT Biopharma over the last few years. It is GT Biopharma's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GT Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Ebitda | 10 Years Trend |
|
Ebitda |
| Timeline |
GTBP Ebitda Regression Statistics
| Arithmetic Mean | (24,111,720) | |
| Geometric Mean | 10,019,566 | |
| Coefficient Of Variation | (145.70) | |
| Mean Deviation | 22,395,979 | |
| Median | (13,576,000) | |
| Standard Deviation | 35,130,360 | |
| Sample Variance | 1234.1T | |
| Range | 136.9M | |
| R-Value | (0.23) | |
| Mean Square Error | 1259.7T | |
| R-Squared | 0.05 | |
| Significance | 0.41 | |
| Slope | (1,795,195) | |
| Total Sum of Squares | 17278T |
GTBP Ebitda History
About GT Biopharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include GT Biopharma income statement, its balance sheet, and the statement of cash flows. GT Biopharma investors use historical funamental indicators, such as GT Biopharma's Ebitda, to determine how well the company is positioned to perform in the future. Although GT Biopharma investors may use each financial statement separately, they are all related. The changes in GT Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GT Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GT Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GT Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBITDA | -13.6 M | -14.3 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.